Compare Novavax Inc (NVAX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Snowflake Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Snowflake Inc trades at $368.89 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 66.6× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 3,986,549). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Snowflake Inc for 54 Days on average.
| NVAX | SNOW | |
|---|---|---|
Market Cap | $1.82B | $121.15B |
Volume | 6,198,505 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $12.75 | $368.89 |
52-Week Low | $6.22 | $121.11 |
Typical Hold Time | 59 Days | 54 Days |
Enterprise Value | $1.39B | $121.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Snowflake (SNOW) trades at $343.40, up 3.17% with strong technical momentum and bullish moving average signals. The company shows impressive revenue growth from $1.2B in 2022 to $3.63B in 2025, though it remains unprofitable with a -20.07% net margin. Recent earnings beats and a $3.75B convertible note offering highlight strategic positioning in the AI data cloud market. Analyst consensus is strongly bullish with 81% buy ratings and a $418 price target, representing 22% upside potential.
Snowflake presents a growth-over-profits investment case with expanding revenue and market leadership in data cloud services. Key opportunities include AI integration partnerships and enterprise adoption, while risks center on persistent losses, high valuation multiples (P/S 21.75), and competitive pressure from cloud giants. The stock's technical strength and Wall Street optimism suggest continued upside if execution matches growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
